Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Price Target

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Jan 20, 2021 12:57pm

114 Views

Post# 32334320

RE:RE:RE:RE:Price Target

The CFO doesn't have the skills to sell and it seems like he is not that competent as a CFO either so he should not be presenting company again.
Paul should take over that roll until the IR lady get her act together.
Inventive which many have considered as a suitable comps is near all time high with a market cap over $700 k vs THTX's less than $200 k so darn right "there is no room for failures anymore".

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market